Literature DB >> 17259908

Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes.

Marie Gueudin1, Jean Christophe Plantier, Véronique Lemée, Marie Paule Schmitt, Loic Chartier, Thomas Bourlet, Annick Ruffault, Florence Damond, Muriel Vray, François Simon.   

Abstract

OBJECTIVES: We conducted a comparison of the Abbott Molecular RealTime (Rungis, France) and Roche Diagnostics Cobas Taqman (Meylan, France) automated nucleic acid extraction and real-time polymerase chain reaction (PCR) amplification systems for their capacity to quantify HIV RNA of various subtypes. The systems were tested on culture supernatants belonging to HIV-1 group M (n = 29), HIV-1 group O (n = 8), and HIV-2 (n = 7). We also tested 88 plasma samples from patients infected with HIV-1 group M (B-D [n = 7], A-CRF01 [n = 16], CRF02 [n = 49], and other strains [n = 16]).
RESULTS: The Abbott RealTime system quantified all 29 HIV-1 group M supernatants. One of these samples was not detected by the Roche Cobas TaqMan system. The Abbott RealTime system quantified 7 HIV-1 group O strains. Neither technique cross-reacted with HIV-2. The 79% intraclass correlation coefficient for the 88 plasma samples was barely acceptable, but 4 plasma samples were underestimated by more than 1 log by the Roche Cobas TaqMan system. Similar values were obtained for subtype B and D strains with the tests, indicating that the primers and probes are suitable for these strains. In contrast, the large differences observed with other subtypes, particularly CRF02, show the importance of primer and probe selection.
CONCLUSION: The limitation of real-time PCR to span the entire diversity of HIV must be taken into account during treatment monitoring, resistance studies, and clinical trials.

Entities:  

Mesh:

Year:  2007        PMID: 17259908     DOI: 10.1097/QAI.0b013e31803260df

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  48 in total

1.  Performance of the novel Qiagen artus QS-RGQ viral load assays compared to that of the Abbott RealTime system with genetically diversified HIV and hepatitis C Virus plasma specimens.

Authors:  Jan Felix Drexler; Ulrike Reber; Andrea Wuttkopf; Anna Maria Eis-Hübinger; Christian Drosten
Journal:  J Clin Microbiol       Date:  2012-03-07       Impact factor: 5.948

2.  Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.

Authors:  Agnès Depatureaux; Charlotte Charpentier; Gilles Collin; Marie Leoz; Diane Descamps; Aurélia Vessière; Florence Damond; Dominique Rousset; Françoise Brun-Vézinet; Jean-Christophe Plantier
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

3.  Performance of NucliSens HIV-1 EasyQ Version 2.0 compared with six commercially available quantitative nucleic acid assays for detection of HIV-1 in China.

Authors:  Sihong Xu; Aijing Song; Jianhui Nie; Xiuhua Li; Youchun Wang
Journal:  Mol Diagn Ther       Date:  2010-10-01       Impact factor: 4.074

4.  Dynamics of two separate but linked HIV-1 CRF01_AE outbreaks among injection drug users in Stockholm, Sweden, and Helsinki, Finland.

Authors:  Helena Skar; Maria Axelsson; Ingela Berggren; Anders Thalme; Katarina Gyllensten; Kirsi Liitsola; Henrikki Brummer-Korvenkontio; Pia Kivelä; Erika Spångberg; Thomas Leitner; Jan Albert
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

5.  HIV-1 load comparison using four commercial real-time assays.

Authors:  Thomas Bourlet; Anne Signori-Schmuck; Laurent Roche; Vinca Icard; Henia Saoudin; Mary-Anne Trabaud; Jean-Claude Tardy; Patrice Morand; Bruno Pozzetto; René Ecochard; Patrice André
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

6.  Evaluation of the Abbott investigational use only realtime HIV-1 assay and comparison to the Roche Amplicor HIV-1 monitor test, version 1.5.

Authors:  Michael T Pyne; Eric Q Konnick; Amit Phansalkar; David R Hillyard
Journal:  J Mol Diagn       Date:  2009-05-21       Impact factor: 5.568

7.  Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in Angola: evidence for low level of transmitted drug resistance.

Authors:  Inês Bártolo; Cheila Rocha; José Bartolomeu; António Gama; Marlene Fonseca; Ana Mendes; Filipa Cristina; Sven Thamm; Marta Epalanga; Patrícia Cavaco Silva; Nuno Taveira
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

8.  Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes.

Authors:  M Wirden; R Tubiana; F Marguet; I Leroy; A Simon; M Bonmarchand; Z Ait-Arkoub; R Murphy; A G Marcelin; C Katlama; V Calvez
Journal:  J Clin Microbiol       Date:  2009-03-18       Impact factor: 5.948

9.  Genotype 3 diversity and quantification of hepatitis E virus RNA.

Authors:  Florence Abravanel; Karine Sandres-Saune; Sebastien Lhomme; Martine Dubois; Jean-Michel Mansuy; Jacques Izopet
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

10.  Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays.

Authors:  F Damond; B Roquebert; A Bénard; G Collin; M Miceli; P Yéni; F Brun-Vezinet; D Descamps
Journal:  J Clin Microbiol       Date:  2007-08-22       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.